About Amicus Therapeutics
Amicus Therapeutics is a company based in Philadelphia (United States) founded in 2002 was acquired by BioMarin Pharmaceutical in December 2025.. Amicus Therapeutics has raised $91 million across 13 funding rounds from investors including BioMarin Pharmaceutical, Blackstone and Frazier Healthcare Partners. The company has 499 employees as of December 31, 2024. Amicus Therapeutics has completed 2 acquisitions, including Callidus Biopharma and Scioderm. Amicus Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Philadelphia, United States
- Employees 499 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Amicus Therapeutics, Inc.
-
Annual Revenue
$528.29 M32.29as on Dec 31, 2024
-
Net Profit
$-56.11 M62.99as on Dec 31, 2024
-
EBITDA
$42.61 M164.93as on Dec 31, 2024
-
Total Equity Funding
$91 M (USD)
in 13 rounds
-
Latest Funding Round
$30 M (USD), Post-IPO
Oct 02, 2023
-
Investors
BioMarin Pharmaceutical
& 10 more
-
Employee Count
499
as on Dec 31, 2024
-
Investments & Acquisitions
Callidus Biopharma
& 1 more
-
Acquired by
BioMarin Pharmaceutical
(Dec 19, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Amicus Therapeutics
Amicus Therapeutics is a publicly listed company on the NASDAQ with ticker symbol FOLD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Leadership Team
50 people
Software Development Team
38 people
Legal and Compliance
11 people
Human Resources and Administration
9 people
Senior Team
9 people
Sales and Marketing
9 people
Operations Team
6 people
Product Management Team
4 people
Unlock access to complete
Funding Insights of Amicus Therapeutics
Amicus Therapeutics has successfully raised a total of $91M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Post-IPO — $30.0M
-
First Round
First Round
(01 Jul 2002)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Post-IPO - Amicus Therapeutics | Valuation |
investors |
|
| Feb, 2018 | Amount | Post-IPO - Amicus Therapeutics | Valuation |
investors |
|
| Apr, 2017 | Amount | Post-IPO - Amicus Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Amicus Therapeutics
Amicus Therapeutics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include BioMarin Pharmaceutical, Blackstone and Frazier Healthcare Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investment management is provided across multiple asset classes.
|
Founded Year | Domain | Location | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Founded Year | Domain | Location | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Amicus Therapeutics
Amicus Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Callidus Biopharma and Scioderm. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Topical therapies are developed for chronic skin diseases treatment.
|
2012 | ||||
|
Enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs)
|
2010 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Amicus Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Amicus Therapeutics Comparisons
Competitors of Amicus Therapeutics
Amicus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Amicus Therapeutics
Frequently Asked Questions about Amicus Therapeutics
When was Amicus Therapeutics founded?
Amicus Therapeutics was founded in 2002.
Where is Amicus Therapeutics located?
Amicus Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Who is the current CEO of Amicus Therapeutics?
Bradley L Campbell is the current CEO of Amicus Therapeutics.
Is Amicus Therapeutics a funded company?
Amicus Therapeutics is a funded company, having raised a total of $91M across 13 funding rounds to date. The company's 1st funding round was a Post-IPO of $21.79M, raised on Jul 01, 2002.
How many employees does Amicus Therapeutics have?
As of Dec 31, 2024, the latest employee count at Amicus Therapeutics is 499.
What is the annual revenue of Amicus Therapeutics?
Annual revenue of Amicus Therapeutics is $528.29M as on Dec 31, 2024.
What does Amicus Therapeutics do?
Amicus Therapeutics was founded in 2002 and is headquartered in Philadelphia, United States. Operations center on the biotechnology sector, where small-molecule therapies for rare and orphan diseases are advanced. A pipeline of pharmacological chaperones targets lysosomal storage disorders such as Fabry, Pompe, and Gaucher diseases. Key candidates include migalastat, an oral treatment for Fabry disease, and SD-101 for the genetic disorder Epidermolysis Bullosa.
Who are the top competitors of Amicus Therapeutics?
Amicus Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Is Amicus Therapeutics publicly traded?
Yes, Amicus Therapeutics is publicly traded on NASDAQ under the ticker symbol FOLD.
How many acquisitions has Amicus Therapeutics made?
Amicus Therapeutics has made 2 acquisitions, including Callidus Biopharma, and Scioderm.
Who are Amicus Therapeutics's investors?
Amicus Therapeutics has 11 investors. Key investors include BioMarin Pharmaceutical, Blackstone, Frazier Healthcare Partners, Canaan, and The Michael J. Fox Foundation.
What is Amicus Therapeutics's ticker symbol?
The ticker symbol of Amicus Therapeutics is FOLD on NASDAQ.